Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 18c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.42), $0.18 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $21.43 million versus the consensus estimate of $18.9 million.

The Company is providing the following financial guidance:

• Net product revenue of $105 million to $120 million for full-year 2022
• Year-end 2022 cash, cash equivalents, and short-term investments in the range of $90 million to $110 million
• Cash flow breakeven by year-end 2023, which assumes performance is consistent with annual net product revenues guidance

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Qualcomm investor day to detail data center plans Wednesday